BC
ICPT

Brinker Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Brinker Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,136
Closed -$355K – 904
2017
Q1 		$355K Sell
3,136
-576
-16% -$67.2K 0.02% 720
2016
Q4 		$403K Buy
+3,712
New +$442K 0.02% 501

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Brinker Capital's ICPT Position: Q2 2017 in Review

Brinker Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2017, closing a stake of 3,136 shares — an estimated $355K sold.

Brinker Capital first reported a position in ICPT in Q4 2016 and held it in 2 quarters. The position peaked at $403K in Q4 2016. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2017.

  • Brinker Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Brinker Capital sold 3,136 Intercept Pharmaceuticals, Inc. shares in Q2 2017, an estimated $355K.
  • Brinker Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
  • Brinker Capital's Intercept Pharmaceuticals, Inc. position peaked at $403K in Q4 2016.
  • 167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2017.

Based on Brinker Capital's 13F filing for Q2 2017, filed 14 Aug 2017.